Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26553
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSherry, Norelle L-
dc.contributor.authorLee, Robyn S-
dc.contributor.authorGorrie, Claire L-
dc.contributor.authorKwong, Jason C-
dc.contributor.authorStuart, Rhonda L-
dc.contributor.authorKorman, Tony M-
dc.contributor.authorMarshall, Caroline-
dc.contributor.authorHiggs, Charlie-
dc.contributor.authorChan, Hiu Tat-
dc.contributor.authorGraham, Maryza-
dc.contributor.authorJohnson, Paul D R-
dc.contributor.authorLeroi, Marcel J-
dc.contributor.authorReed, Caroline-
dc.contributor.authorRichards, Michael J-
dc.contributor.authorSlavin, Monica A-
dc.contributor.authorWorth, Leon J-
dc.contributor.authorHowden, Benjamin P-
dc.contributor.authorGrayson, M Lindsay-
dc.date2020-11-26-
dc.date.accessioned2021-05-24T05:45:01Z-
dc.date.available2021-05-24T05:45:01Z-
dc.date.issued2021-05-
dc.identifier.citationInfection Control and Hospital Epidemiology 2021; 42(5): 573-581en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26553-
dc.description.abstractTo conduct a pilot study implementing combined genomic and epidemiologic surveillance for hospital-acquired multidrug-resistant organisms (MDROs) to predict transmission between patients and to estimate the local burden of MDRO transmission. Pilot prospective multicenter surveillance study. The study was conducted in 8 university hospitals (2,800 beds total) in Melbourne, Australia (population 4.8 million), including 4 acute-care, 1 specialist cancer care, and 3 subacute-care hospitals. All clinical and screening isolates from hospital inpatients (April 24 to June 18, 2017) were collected for 6 MDROs: vanA VRE, MRSA, ESBL Escherichia coli (ESBL-Ec) and Klebsiella pneumoniae (ESBL-Kp), and carbapenem-resistant Pseudomonas aeruginosa (CRPa) and Acinetobacter baumannii (CRAb). Isolates were analyzed and reported as routine by hospital laboratories, underwent whole-genome sequencing at the central laboratory, and were analyzed using open-source bioinformatic tools. MDRO burden and transmission were assessed using combined genomic and epidemiologic data. In total, 408 isolates were collected from 358 patients; 47.5% were screening isolates. ESBL-Ec was most common (52.5%), then MRSA (21.6%), vanA VRE (15.7%), and ESBL-Kp (7.6%). Most MDROs (88.3%) were isolated from patients with recent healthcare exposure.Combining genomics and epidemiology identified that at least 27.1% of MDROs were likely acquired in a hospital; most of these transmission events would not have been detected without genomics. The highest proportion of transmission occurred with vanA VRE (88.4% of patients). Genomic and epidemiologic data from multiple institutions can feasibly be combined prospectively, providing substantial insights into the burden and distribution of MDROs, including in-hospital transmission. This analysis enables infection control teams to target interventions more effectively.en
dc.language.isoeng
dc.titlePilot study of a combined genomic and epidemiologic surveillance program for hospital-acquired multidrug-resistant pathogens across multiple hospital networks in Australia.en
dc.typeJournal Articleen
dc.identifier.journaltitleInfection Control and Hospital Epidemiologyen
dc.identifier.affiliationMicrobiologyen
dc.identifier.affiliationDepartment of Microbiology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australiaen
dc.identifier.affiliationNational Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationMicrobiological Diagnostic Unit (MDU) Public Health Laboratory, Department of Microbiology & Immunology at the Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Microbiology & Immunology at the Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationInfectious Diseasesen
dc.identifier.affiliationDepartment of Infectious Diseases, Monash Health, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Microbiology, Monash Health, Clayton, Victoria, Australiaen
dc.identifier.affiliationInfection Prevention & Surveillance Service, Victorian Infectious Diseases Service, Melbourne Health, Parkville, Victoria, Australiaen
dc.identifier.affiliationPeter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australiaen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationDepartment of Microbiology, Melbourne Health, Parkville, Victoria, Australiaen
dc.identifier.doi10.1017/ice.2020.1253en
dc.type.contentTexten
dc.identifier.orcid0000-0002-7789-8360en
dc.identifier.pubmedid34008484
local.name.researcherGrayson, M Lindsay
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

120
checked on Feb 17, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.